Clinical Trials
98 trialsMK-1045-005
Merck Sharp & Dohme LLC
CASSIOPEIA
Novartis
MK-9999-01A
Merck Sharp & Dohme LLC
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
SYRUS
AstraZeneca
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
KEYNOTE145
Acerta Pharma BV
ALLight
AstraZeneca
Study of Out of Specification for Tisagenlecleucel
Novartis
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
ADAPT-HEM
Beijing Biotech
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Atalanta-1
Lakefront Biotherapeutics NV
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
ZUMA-25
Gilead Sciences
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
RELATIVITY-069
Bristol-Myers Squibb
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
PeproMene Bio, Inc.
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Chongqing Precision Biotech Co., Ltd
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
B-ALL
Juventas Cell Therapy Ltd.
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
Shenzhen Genocury Biotech Co., Ltd.
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Beijing Yongtai Ruike Biotechnology Company Ltd
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Boehringer Ingelheim
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
BIANCA
Novartis
ELIANA
Novartis
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Novartis
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Hrain Biotechnology Co., Ltd.
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Eden BioCell Ltd.
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.